Skip to main content

Table 3 Five- and 10-year cumulative incidence of cancer recurrence of breast cancer patients with local R0 resection by age, tumor characteristics and provided recommended treatments

From: Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis – results from a registry-based study from Germany

Category/treatment

 

N

5-year CI

10-year CI

p-value

 

PE

95% CI

PE

95% CI

Overall

 

5311

10.4

[9.6, 11.3]

15.9

[14.8, 17.0]

 

Age

<  70 years

3714

11.2

[10.2, 12.3]

17.2

[16.0, 18.6]

< 0.001

 

≥ 70 years

1597

8.7

[7.4, 10.2]

12.6

[11.0, 14.5]

Clinical stage

T1/2N0

2918

5.6

[4.8, 6.5]

9.4

[8.3, 10.7]

< 0.001

 

T1/2N+

1613

14.8

[13.1, 16.6]

23.1

[20.9, 25.5]

T3/4N0

124

16.1

[10.8, 24.2]

23.5

[16.7, 33.1]

T3/4N+

409

26.9

[22.9, 31.6]

34.3

[29.8, 39.6]

missing

247

9.0

[6.0, 13.4]

9.9

[6.7, 14.5]

Morphology

invasive ductal

3690

10.9

[10.0, 12.0]

16.2

[14.9, 17.5]

0.075

 

invasive lobular

758

9.7

[7.8, 12.0]

17.8

[15.0, 21.1]

mixed type

459

9.0

[6.7, 12.0]

14.3

[11.3, 18.2]

other

404

9.0

[6.6, 12.3]

11.1

[8.3, 14.9]

Histopathologic grade

1

447

2.7

[1.5, 4.7]

5.9

[3.9, 8.9]

< 0.001

 

2

3332

8.5

[7.6, 9.5]

13.9

[12.6, 15.2]

3/4

1497

16.8

[15.0, 18.8]

23.0

[20.9, 25.4]

missing

35

17.6

[8.4, 36.8]

21.8

[11.0, 43.1]

HR expression

positivea

4132

8.3

[7.5, 9.2]

14.0

[12.9, 15.2]

< 0.001

 

negative

775

22.8

[20.0, 26.0]

27.1

[24.0, 30.5]

missing

404

9.0

[6.6, 12.3]

12.6

[9.4, 16.8]

HER2/neu expression

positiveb

972

13.3

[11.3, 15.6]

21.7

[18.9, 24.8]

< 0.001

 

negative

2941

9.6

[8.6, 10.7]

14.0

[12.7, 15.5]

missing

1398

10.2

[8.7, 11.9]

15.6

[13.8, 17.7]

Subtype based on immunohistochemical surrogates

‚HR positive‘

4132

8.3

[7.5, 9.2]

14.0

[12.9, 15.2]

< 0.001

 

‚HER2/neu positive‘c

234

22.8

[18.0, 28.9]

28.0

[22.4, 34.9]

‚triple negative‘d

376

23.2

[19.3, 27.9]

25.6

[21.4, 30.5]

missing

569

12.7

[10.3, 15.8]

17.8

[14.7, 21.6]

BCS

T1/2N0

198

5.6

[3.1, 10.0]

7.7

[4.4, 13.4]

BCS + RT

T1/2N0

2114

4.6

[3.8, 5.6]

8.4

[7.2, 9.8]

Mastectomy

T1/2N0

606

9.1

[7.1, 11.8]

13.5

[10.9, 16.7]

(BCS + RT or mastectomy) + HT

T1/2N0 HR positivea

1749

3.9

[3.1, 4.9]

8.2

[6.9, 9.8]

(BCS + RT or mastectomy) + CT

T1/2N0 HR negative

277

12.3

[9.0, 16.8]

15.5

[11.6, 20.6]

(BCS + RT or mastectomy) + HT (if HR positive) + CT (if HR negative) + TT

T1/2N0 HER2/neu positive

73

2.7

[0.7, 10.9]

2.7

[0.7, 10.9]

(BCS or mastectomy) + RT + CT + HT

T1/2N+ HR positivea

554

12.0

[9.6, 15.1]

19.5

[16.1, 23.7]

(BCS or mastectomy) + RT + CT

T1/2N+ HR negative

156

28.4

[22.1, 36.5]

36.9

[29.6, 46.0]

(BCS or mastectomy) + RT + CT + HT (if HR positive) + TT

T1/2N+ HER2/neu positive

51

19.6

[11.2, 34.4]

21.9

[12.9, 37.2]

MAST + RT + CT + HT

T3/4 HR positivea

88

26.1

[18.4, 37.2]

34.0

[24.7, 46.9]

MAST + RT + CT

T3/4 HR negative

50

48.0

[35.8, 64.3]

52.2

[39.8, 68.5]

  1. The sample includes female patients with primary invasive breast cancer (ICD-10 code: C50) without distant metastases from Saarland diagnosed between 1999 and 2009. CI cumulative incidence, PE point estimate of CI, 95% CI 95% confidence interval of PE, T, N T and N category of TNM classification, HR hormone receptor, HER2/neu human epidermal growth factor receptor 2, BCS breast conserving surgery, RT radiotherapy, CT chemotherapy, HT hormonal (anti-estrogen) treatment, TT targeted therapy (trastuzumab). aincludes tumors with mixed HR expression (either estrogen or progesterone receptor positive), bincludes tumors with borderline expression of HER2/neu, cHER2/neu positive, but HR negative, dboth HR negative and HER2/neu negative
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us